CA2451433C - Oligopeptide transporter 1 inhibitor - Google Patents

Oligopeptide transporter 1 inhibitor Download PDF

Info

Publication number
CA2451433C
CA2451433C CA002451433A CA2451433A CA2451433C CA 2451433 C CA2451433 C CA 2451433C CA 002451433 A CA002451433 A CA 002451433A CA 2451433 A CA2451433 A CA 2451433A CA 2451433 C CA2451433 C CA 2451433C
Authority
CA
Canada
Prior art keywords
prx
cdx
tissue
val
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002451433A
Other languages
English (en)
French (fr)
Other versions
CA2451433A1 (en
Inventor
Akira Tsuji
Ikumi Tamai
Yoshimichi Sai
Noubuhiko Yui
Toru Oya
Ken-Ichi Miyamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Publication of CA2451433A1 publication Critical patent/CA2451433A1/en
Application granted granted Critical
Publication of CA2451433C publication Critical patent/CA2451433C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Polyethers (AREA)
CA002451433A 2001-06-21 2002-06-19 Oligopeptide transporter 1 inhibitor Expired - Fee Related CA2451433C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001188843A JP3942846B2 (ja) 2001-06-21 2001-06-21 組織特異的トランスポーター阻害剤
JP2001-188843 2001-06-21
PCT/JP2002/006104 WO2003000285A1 (fr) 2001-06-21 2002-06-19 Inhibiteur de transporteur specifique de tissu

Publications (2)

Publication Number Publication Date
CA2451433A1 CA2451433A1 (en) 2003-01-03
CA2451433C true CA2451433C (en) 2007-10-30

Family

ID=19027864

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002451433A Expired - Fee Related CA2451433C (en) 2001-06-21 2002-06-19 Oligopeptide transporter 1 inhibitor

Country Status (6)

Country Link
US (1) US7420029B2 (enExample)
EP (1) EP1405644A4 (enExample)
JP (1) JP3942846B2 (enExample)
AU (1) AU2002313242B2 (enExample)
CA (1) CA2451433C (enExample)
WO (1) WO2003000285A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7420079B2 (en) * 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19633268A1 (de) * 1996-08-19 1998-02-26 Hoechst Ag Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung

Also Published As

Publication number Publication date
US7420029B2 (en) 2008-09-02
JP2003002843A (ja) 2003-01-08
JP3942846B2 (ja) 2007-07-11
US20040191211A1 (en) 2004-09-30
CA2451433A1 (en) 2003-01-03
EP1405644A4 (en) 2005-04-06
EP1405644A1 (en) 2004-04-07
AU2002313242B2 (en) 2005-06-16
WO2003000285A1 (fr) 2003-01-03

Similar Documents

Publication Publication Date Title
Omid et al. In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery
US20110224148A1 (en) Carbohydrate-polyamino acid-drug conjugates
JP2003511349A (ja) 薬剤担体としてのポリ（ジペプチド）
CN104096236A (zh) 用于治疗癌症的聚合物紫杉醇结合物和方法
CN101489592A (zh) 考布他汀的高分子量偶联物
CN108148193A (zh) 一种含胆酸的高分子材料及其修饰的脂质体
CN103222963B (zh) 生长抑素冻干粉针剂
CA2451433C (en) Oligopeptide transporter 1 inhibitor
CN104341488A (zh) c(LyP-1)多肽及其构建的纳米递药系统和应用
Xing et al. Polymeric liposomes targeting dual transporters for highly efficient oral delivery of paclitaxel
Shi et al. PDT-sensitized ROS-responsive dextran nanosystem for maximizing antitumor potency of multi-target drugs
US20090082266A1 (en) Conjugate of water-soluble hyaluronic acid modification product with glp-a analogue
CN107337710A (zh) 一种抗高血压活性肽The‑The‑Pro及应用和药物组合物
US20250320251A1 (en) Pharmaceutical compositions comprising novel cyclic peptides
CN105315350A (zh) 抗肿瘤血管生成多肽mPEG-Mal-Cys-AS16
CN100531801C (zh) 聚乙二醇化藤黄酸类前药、其制备方法、制剂及制备药物的用途
JP2018012694A (ja) ラパマイシン類結合ブロック共重合体
CN107312064A (zh) 一种抗高血压活性肽GABA‑The‑Pro及应用和药物组合物
CN110734475A (zh) 一种具有α-葡萄糖苷酶抑制活性的寡肽及其应用
CN110787302B (zh) 一种pH敏感青蒿琥酯聚合物前药及其制备方法、治疗结肠癌的药物组合物
CN104744584B (zh) 一种聚乙二醇-rTRAIL突变体三聚体-海兔毒素偶联物及其制备方法和应用
CN107337712A (zh) 一种抗高血压活性肽Orn‑Hyp‑Pro及应用和药物组合物
CN107236024A (zh) 一种赖氨酸分枝二聚多肽及其应用
CN101220084A (zh) 聚乙二醇修饰的三价铁亚血红素短肽化合物及制备方法
Bilkova et al. Recent advances in the design and synthesis of prednisolone and methylprednisolone conjugates

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed